Working… Menu
Trial record 91 of 186 for:    BUPRENORPHINE AND NALOXONE

Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01713803
Recruitment Status : Withdrawn (FDA did not require a clinical trial for indication.)
First Posted : October 25, 2012
Last Update Posted : May 4, 2017
Information provided by (Responsible Party):
BioDelivery Sciences International

Brief Summary:
This is a randomized, double blind, placebo controlled study in opioid dependent subjects. Subjects meeting entry criteria will be treated with multiple doses of B-BNX or B-Placebo, with non-responders rescued within 6 hours. Open treatment B-BNX will be administered as follow-up therapy. Clinical efficacy assessments include the clinical opioid withdrawal scale (COWS), subject-rated assessments, and a urine drug screen.

Condition or disease Intervention/treatment Phase
Opioid Dependence Drug: Buprenorphine and naloxone Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Official Title: Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects
Actual Primary Completion Date : May 1, 2017
Actual Study Completion Date : May 1, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Sugar pill Drug: Buprenorphine and naloxone
Experimental: buprenorphine and nalaxone Drug: Buprenorphine and naloxone

Primary Outcome Measures :
  1. The mean change in clinical opioid withdrawal scale (COWS) total score from Baseline to 6 hours following the initial dose

Secondary Outcome Measures :
  1. The percentage of subjects with a negative result on the urine drug screen at Day 7
  2. The percentage of subjects with a clinical opioid withdrawal scale (COWS) total score ≤4 at 6 hours after the initial study drug dose

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent obtained prior to any study procedure being performed
  • Subject is a male or non-lactating female with a negative urine pregnancy test
  • Subject is aged 18 to 65 years, inclusive
  • Current diagnosis of opioid dependence or addiction per the Diagnostic and Statistical Manual of Mental Disorders - 4th edition (text revision) (DSM-IV-TR) criteria including physical dependence on opioids
  • Daily short-acting opiate use of at least 60 mg morphine equivalent no opioid use for at least 12 hours prior to Screening with positive opiate result on urine drug screen
  • Clinical opioid withdrawal scale (COWS) score ≥9
  • Subject is in good general health in the judgment of the Investigator as determined from the physical and oral examination findings.

Exclusion Criteria:

  • Use of a long-acting opioid within the last 72 hours
  • Use of an investigational drug or device within the last 30 days
  • History of hypersensitivity, allergy, or intolerance to buprenorphine, naloxone, or related drugs
  • Immediate suicidal risk, as determined by meeting any of the following:

    1. History of suicidal ideation ≤ 3 months prior to Baseline with a score of 4 (intent to act) or 5 (specific plan and intent) on the eC-SSRS
    2. History of suicidal behavior ≤1 year prior to Baseline (actual attempt, interrupted attempt, aborted attempt and/or preparatory acts/behavior) on the eC-SSRS
  • A history or current evidence of any clinically significant disorder or any other condition which in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01713803

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States, 35215
Sponsors and Collaborators
BioDelivery Sciences International

Layout table for additonal information
Responsible Party: BioDelivery Sciences International Identifier: NCT01713803     History of Changes
Other Study ID Numbers: BNX-350
First Posted: October 25, 2012    Key Record Dates
Last Update Posted: May 4, 2017
Last Verified: May 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists